[go: up one dir, main page]

RU2018108353A - Комбинация, включающая иммуностимулирующие олигонуклеотиды - Google Patents

Комбинация, включающая иммуностимулирующие олигонуклеотиды Download PDF

Info

Publication number
RU2018108353A
RU2018108353A RU2018108353A RU2018108353A RU2018108353A RU 2018108353 A RU2018108353 A RU 2018108353A RU 2018108353 A RU2018108353 A RU 2018108353A RU 2018108353 A RU2018108353 A RU 2018108353A RU 2018108353 A RU2018108353 A RU 2018108353A
Authority
RU
Russia
Prior art keywords
paragraphs
combination according
sequence
combination
chain
Prior art date
Application number
RU2018108353A
Other languages
English (en)
Other versions
RU2766693C2 (ru
RU2018108353A3 (ru
Inventor
Маттьяс ШРОФФ
Мануэль Шмидт
Керстин КАПП
Альфредо ЦУРЛО
Original Assignee
Мологен Аг
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Мологен Аг filed Critical Мологен Аг
Publication of RU2018108353A publication Critical patent/RU2018108353A/ru
Publication of RU2018108353A3 publication Critical patent/RU2018108353A3/ru
Application granted granted Critical
Publication of RU2766693C2 publication Critical patent/RU2766693C2/ru

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/117—Nucleic acids having immunomodulatory properties, e.g. containing CpG-motifs
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7088—Compounds having three or more nucleosides or nucleotides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/39541—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against normal tissues, cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2818—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against CD28 or CD152
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2827—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against B7 molecules, e.g. CD80, CD86
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/30—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/111—General methods applicable to biologically active non-coding nucleic acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/10—Type of nucleic acid
    • C12N2310/17—Immunomodulatory nucleic acids
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/30—Chemical structure
    • C12N2310/32—Chemical structure of the sugar
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/30—Chemical structure
    • C12N2310/34—Spatial arrangement of the modifications
    • C12N2310/344—Position-specific modifications, e.g. on every purine, at the 3'-end
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/50—Physical structure
    • C12N2310/53—Physical structure partially self-complementary or closed
    • C12N2310/531—Stem-loop; Hairpin
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/50—Physical structure
    • C12N2310/53—Physical structure partially self-complementary or closed
    • C12N2310/532—Closed or circular
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2320/00—Applications; Uses
    • C12N2320/30—Special therapeutic applications
    • C12N2320/31—Combination therapy

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Genetics & Genomics (AREA)
  • Organic Chemistry (AREA)
  • Biomedical Technology (AREA)
  • Immunology (AREA)
  • General Health & Medical Sciences (AREA)
  • Molecular Biology (AREA)
  • Medicinal Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Engineering & Computer Science (AREA)
  • Biotechnology (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Microbiology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Plant Pathology (AREA)
  • Physics & Mathematics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Epidemiology (AREA)
  • Mycology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Cell Biology (AREA)
  • Endocrinology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)

Claims (28)

1. Комбинация, включающая следующие компоненты:
а. первую группу, включающую химическое соединение или молекулу, связывающиеся по меньшей мере с одной из молекул из группы: ПКГ-1, ПКГ-L1, ОХ40, TIM-3, LAG3, CD137 (4-1ВВ) и влияющую на их функцию Т-клеточных регуляторов; а также
б. вторую группу, включающую некодирующую последовательность дезоксирибонуклеиновых кислот, в которую для лечения вирусных инфекций входит, по меньшей мере, один мотив последовательности N1N2CGN3N4, где N означает нуклеотид, содержащий А, С, Т или G; С - дезоксицитидин; G - дезоксигуанозин; А - дезоксиаденозин; а Т - дезокситимидин.
2. Комбинация, по п. 1, где N1N2 представляет собой элемент групп GT, GG, GA, AT и АА, a N3N4 представляет собой элемент групп СТ, TG и ТТ.
3. Комбинация по любому из пп. 1-2, где некодирующая последовательность дезоксирибонуклеиновых кислот может быть представлена в следующих видах: линейная последовательность с незамкнутой с двух сторон цепью; линейная последовательность с незамкнутой двойной цепью с одной стороны и одноцепочечной шпилькой с другой; гантелеобразный конструкт, частично одноцепочечный, с ковалентно замкнутой цепью дезоксирибонуклеиновых кислот.
4. Комбинация по любому из пп. 1-2, где регуляторы Т-клеток включают ингибиторы контрольных точек иммунной системы и сопутствующие стимулирующие молекулы иммунной системы.
5. Комбинация по любому из пп. 1-2, содержащая по меньшей мере три мотива последовательности N1N2CGN3N4.
6. Комбинация по любому из пп. 1-2, где линейная некодирующая последовательность с неразветвленной цепью дезоксирибонуклеиновых кислот включает по меньшей мере один нуклеотид в L-образной конформации.
7. Комбинация по любому из пп. 1-2, где один из пяти концевых нуклеотидов, расположенных на 5'- и/или 3'-конце одиночной цепи ДНК с линейной некодирующей последовательностью дезоксирибонуклеиновых кислот с неразветвленной цепью, находится в L-образной конформации.
8. Комбинация по любому из пп. 1-2, включающая по меньшей мере одну из следующих последовательностей:
а. GTTCCTGGAG ACGTTCTTAG GAACGTTCTC CTTGACGTTG GAGAGAAC (идент. № последовательности: 1), или
б. ACCTTCCTTG TACTAACGTT GCCTCAAGGA AGGTTGATCT TCATAACGTT GCCTAGATCA (идент. № последовательности: 2), или
в. AACGTTCTTCGGGG CGTT (идент. № последовательности: 3), или
г. AGGTGGTAAC CCCTAGGGGT TACCACCTTC ATCGTCGTTT TGTCGTTTTG TCGTTCTT (идент. № последовательности: 4).
9. Комбинация по любому из пп. 1-2, где некодирующая последовательность дезоксирибонуклеиновых кислот имеет длину от 40 до 200 нуклеотидов.
10. Комбинация, по п. 9, где последовательность с) является частью последовательности CCTAGGGGTT АССАССТТСА TTGGAAAACG TTCTTCGGGG CGTTCTTAGG TGGTAACC CCTAGGGGTT АССАССТТСА TTGGAAAACG TTCTTCGGGG CGTTCTTAGG TGGTAACC (идент. № последовательности: 5).
11. Комбинация по любому из пп. 1-2, где некодирующая последовательность дезоксирибонуклеиновых кислот имеет длину от 48 до 116 нуклеотидов.
12. Комбинация по любому из пп. 1-2, где вышеуказанный мотив последовательности N1N2CGN3N4 является частью одноцепочечного участка.
13. Комбинация по любому из пп. 1-2, где молекула, связанная с Т-клеточными регуляторами, представляет собой антитело.
14. Комбинация по любому из пп. 1-2, компоненты обеих групп представлены в твердой, жидкой или газообразной форме, а вводимая доза составляет 15 мг/кг веса максимально.
15. Способ, включающий этап введения компонентов комбинации, представленной в любом из пп. 1-13 формулы изобретения, одновременно, с чередованием или последовательно.
16. Способ по п. 15, где некодирующую последовательность дезоксирибонуклеиновых кислот используют до химического вещества или молекулы для влияния на Т-клеточные регуляторы.
17. Применение комбинации по любому из пп. 1-13 в качестве лекарственного средства.
18. Применение комбинации, по любому из пп. 1-13, для лечения рака, аутоиммунного заболевания или воспаления.
19. Применение комбинации, по п. 17, где соединения комбинации вводят одновременно, с чередованием или последовательно.
20. Применение комбинации, по любому из пп. 1-13, для изготовления фармкомпозиции на основе комбинации.
21. Применение комбинации, по п. 19, в которой фармацевтическое вещество высвобождает соединения комбинации одновременно, с чередованием или последовательно.
22. Применение комбинации, по любому из пп. 1-13, в качестве адъюванта при терапевтической или профилактической вакцинации.
RU2018108353A 2015-09-09 2016-09-09 Комбинация, включающая иммуностимулирующие олигонуклеотиды RU2766693C2 (ru)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
LU92821A LU92821B1 (en) 2015-09-09 2015-09-09 Combination comprising immunostimulatory oligonucleotides
LU92821 2015-09-09
PCT/EP2016/071314 WO2017042336A1 (en) 2015-09-09 2016-09-09 Combination comprising immunostimulatory oligonucleotides

Publications (3)

Publication Number Publication Date
RU2018108353A true RU2018108353A (ru) 2019-10-09
RU2018108353A3 RU2018108353A3 (ru) 2020-02-28
RU2766693C2 RU2766693C2 (ru) 2022-03-15

Family

ID=54251700

Family Applications (1)

Application Number Title Priority Date Filing Date
RU2018108353A RU2766693C2 (ru) 2015-09-09 2016-09-09 Комбинация, включающая иммуностимулирующие олигонуклеотиды

Country Status (17)

Country Link
US (3) US10487333B2 (ru)
EP (1) EP3347468B1 (ru)
JP (3) JP2018530530A (ru)
KR (1) KR102411799B1 (ru)
CN (1) CN108138179B (ru)
AU (1) AU2016319214B2 (ru)
CA (1) CA2997319C (ru)
ES (1) ES2905891T3 (ru)
IL (1) IL257921B (ru)
LU (1) LU92821B1 (ru)
MX (1) MX2018002665A (ru)
PL (1) PL3347468T3 (ru)
PT (1) PT3347468T (ru)
RU (1) RU2766693C2 (ru)
SI (1) SI3347468T1 (ru)
WO (1) WO2017042336A1 (ru)
ZA (1) ZA201801001B (ru)

Families Citing this family (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN105579582A (zh) 2013-07-25 2016-05-11 埃克西奎雷股份有限公司 用于预防和治疗用途的作为免疫刺激剂的基于球形核酸的构建体
CA2968531A1 (en) 2014-11-21 2016-05-26 Northwestern University The sequence-specific cellular uptake of spherical nucleic acid nanoparticle conjugates
LU92821B1 (en) 2015-09-09 2017-03-20 Mologen Ag Combination comprising immunostimulatory oligonucleotides
GB2542425A (en) 2015-09-21 2017-03-22 Mologen Ag Means for the treatment of HIV
HK1251158A1 (zh) 2015-09-29 2019-01-25 细胞基因公司 Pd-1结合蛋白及其使用方法
US12202856B2 (en) 2016-05-19 2025-01-21 The General Hospital Corporation Tethered interleukin-2 to its receptor IL-2RBETA, a platform to enhance natural killer and regulatory T cell activity
US11364304B2 (en) 2016-08-25 2022-06-21 Northwestern University Crosslinked micellar spherical nucleic acids
KR102257154B1 (ko) 2016-09-19 2021-05-28 셀진 코포레이션 Pd-1 결합 단백질을 사용하는 면역 질환의 치료 방법
US10766958B2 (en) 2016-09-19 2020-09-08 Celgene Corporation Methods of treating vitiligo using PD-1 binding antibodies
EP3392345A1 (en) 2017-04-22 2018-10-24 Mologen AG Biomarker for small cell lung cancer therapy
US11433131B2 (en) 2017-05-11 2022-09-06 Northwestern University Adoptive cell therapy using spherical nucleic acids (SNAs)
TW201919652A (zh) * 2017-08-31 2019-06-01 德商摩洛基公司 調節腫瘤微環境之ｔｌｒ－９促效劑
WO2019200238A1 (en) 2018-04-14 2019-10-17 Dynavax Technologies Corporation Combinations including a cpg-c type oligonucleotide and a histone deacetylase inhibitor for treating cancer
US20200318200A1 (en) 2019-04-02 2020-10-08 The Brigham And Women's Hospital, Inc. Methods for Identifying Progression of a Primary Melanoma
CN112007149A (zh) * 2019-05-29 2020-12-01 思格(苏州)生物科技有限公司 一种新型复合免疫佐剂及其应用

Family Cites Families (82)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB191115253A (en) 1911-06-30 1912-06-20 Adolph Schneider Improvements in Bottle-filling Machines.
US2382696A (en) 1939-04-01 1945-08-14 Milleville Marie Joseph Mau De Method and apparatus for filling containers
GB684057A (en) 1949-11-30 1952-12-10 Stockholms Bryggerier Ab Machine of the rotatory table type for the treatment of bottles and the like containers
US2699718A (en) 1952-04-10 1955-01-18 Francis X Wright Filling apparatus with beverage preparation mechanism
FR1418965A (fr) 1964-10-14 1965-11-26 Chelle Ets Tireuse de liquides à double utilisation
AU554222B2 (en) 1981-10-13 1986-08-14 Toyo Garasu K.K. Inspecting glass containers
ES2099718T3 (es) 1990-07-02 1997-06-01 Hoechst Ag Analogos de oligonucleotidos con uniones internucleotidicas de 3'-3' o 5'-5' terminales.
DK0748382T3 (da) 1993-09-02 2003-02-17 Ribozyme Pharm Inc Enzymatisk nukleinsyre indeholdende ikke-nukleotid
WO1995026204A1 (en) 1994-03-25 1995-10-05 Isis Pharmaceuticals, Inc. Immune stimulation by phosphorothioate oligonucleotide analogs
US6207646B1 (en) 1994-07-15 2001-03-27 University Of Iowa Research Foundation Immunostimulatory nucleic acid molecules
US20030050263A1 (en) 1994-07-15 2003-03-13 The University Of Iowa Research Foundation Methods and products for treating HIV infection
FR2732971B1 (fr) 1995-04-13 1997-07-04 Genset Sa Oligonucleotide sens inhibiteur de virus herpes simplex (hsv) a structure en haltere
US5856462A (en) 1996-09-10 1999-01-05 Hybridon Incorporated Oligonucleotides having modified CpG dinucleosides
PT1027359E (pt) 1996-10-16 2003-09-30 Ribapharm Inc L-nucleosideos monociclicos analogos e suas utilizacoes
DE19648625A1 (de) 1996-11-13 1998-05-14 Soft Gene Gmbh Mikroprojektil für das Einbringen von Substanzen in Zellen durch ballistischen Transfer
EP0855184A1 (en) 1997-01-23 1998-07-29 Grayson B. Dr. Lipford Pharmaceutical composition comprising a polynucleotide and an antigen especially for vaccination
US6251666B1 (en) 1997-03-31 2001-06-26 Ribozyme Pharmaceuticals, Inc. Nucleic acid catalysts comprising L-nucleotide analogs
US6589940B1 (en) 1997-06-06 2003-07-08 Dynavax Technologies Corporation Immunostimulatory oligonucleotides, compositions thereof and methods of use thereof
US6192481B1 (en) 1998-08-18 2001-02-20 International Business Machines Corporation Structure and method for power sequencing of disk drives in a computer system
DE60015084T2 (de) 1999-02-26 2006-02-16 Chiron S.R.L. Verbesserung der bakterizidaktivität von neisseria antigenen mit cg enthaltende oligonukleotiden
US6977245B2 (en) 1999-04-12 2005-12-20 The United States Of America As Represented By The Department Of Health And Human Services Oligodeoxynucleotide and its use to induce an immune response
US6737066B1 (en) 1999-05-06 2004-05-18 The Immune Response Corporation HIV immunogenic compositions and methods
CA2376992A1 (en) 1999-06-29 2001-01-04 Smithkline Beecham Biologicals S.A. Use of cpg as an adjuvant for hiv vaccine
DE19935756A1 (de) 1999-07-27 2001-02-08 Mologen Forschungs Entwicklung Kovalent geschlossenes Nukleinsäuremolekül zur Immunstimulation
WO2001040515A1 (en) 1999-11-12 2001-06-07 Isis Pharmaceuticals, Inc. Gapped oligomers having site specific chiral phosphorothioate internucleoside linkages
CA2423487C (en) 2000-09-26 2015-12-15 Hybridon, Inc. Modulation of immunostimulatory activity of immunostimulatory oligonucleotide analogs by positional chemical changes
WO2002060476A2 (de) 2001-01-31 2002-08-08 Mologen Forschungs-, Entwicklungs- Und Vertriebs Gmbh Tumorvakzine
CA2452458A1 (en) 2001-07-03 2003-01-16 Isis Pharmaceuticals, Inc. Nuclease resistant chimeric oligonucleotides
CN1310676C (zh) 2001-10-02 2007-04-18 莫洛根股份公司 提高免疫应答的方法
AU2002349278A1 (en) 2001-10-02 2003-04-22 Mologen Ag Dna-expression construct for treatment of infections with leishmaniasis
WO2003035836A2 (en) 2001-10-24 2003-05-01 Hybridon Inc. Modulation of immunostimulatory properties of oligonucleotide-based compounds by optimal presentation of 5' ends
US7276489B2 (en) 2002-10-24 2007-10-02 Idera Pharmaceuticals, Inc. Modulation of immunostimulatory properties of oligonucleotide-based compounds by optimal presentation of 5′ ends
JP2003204793A (ja) 2002-01-15 2003-07-22 Takeda Chem Ind Ltd ウイルス性疾患の予防または治療剤
DE10211558A1 (de) 2002-03-15 2003-10-09 Noxxon Pharma Ag Neue Formen RNAi
US7605138B2 (en) * 2002-07-03 2009-10-20 Coley Pharmaceutical Group, Inc. Nucleic acid compositions for stimulating immune responses
WO2004041183A2 (en) 2002-11-01 2004-05-21 The Regents Of The University Of California Methods of treating pulmonary fibrotic disorders
US8158768B2 (en) 2002-12-23 2012-04-17 Dynavax Technologies Corporation Immunostimulatory sequence oligonucleotides and methods of using the same
US7501503B2 (en) 2002-12-31 2009-03-10 Mcgill University Compositions and methods for inhibiting RNase H activity of retroid reverse transcriptase
ZA200507562B (en) 2003-03-26 2006-11-29 Cytos Biotechnology Ag HIV-peptide-carrier-conjugates
JP4451842B2 (ja) 2003-06-10 2010-04-14 モロゲン・アーゲー 遺伝子治療に用いるための製品
US8188254B2 (en) 2003-10-30 2012-05-29 Coley Pharmaceutical Gmbh C-class oligonucleotide analogs with enhanced immunostimulatory potency
JP2007512845A (ja) 2003-12-02 2007-05-24 アネシバ・インコーポレイテッド Ｎｆ−κｂオリゴヌクレオチドデコイ分子
BRPI0418157A (pt) 2003-12-30 2007-04-17 Mologen Ag terapêutica de tumores alogênicos
CN1918293A (zh) 2004-02-20 2007-02-21 莫洛根股份公司 用于对人及高等动物进行治疗性和预防性免疫刺激的取代的非编码核酸分子
JP3976742B2 (ja) 2004-02-27 2007-09-19 江守商事株式会社 インターフェロンアルファを誘導する免疫刺激オリゴヌクレオチド
WO2005116223A1 (de) 2004-05-28 2005-12-08 Mologen Ag Herstellungsverfahren geeigneter dna-konstrukte zur spezifischen hemmung der genexpression durch rna-interferenz
HUE036894T2 (hu) 2004-06-15 2018-08-28 Idera Pharmaceuticals Inc Immunstimuláló oligonukleotid multimerek
WO2006015560A1 (de) 2004-08-09 2006-02-16 Mologen Ag Immunmodulierendes mittel in verbindung mit chemotherapeutischen massnahmen
US7879992B2 (en) 2005-01-31 2011-02-01 Isis Pharmaceuticals, Inc. Modification of MyD88 splicing using modified oligonucleotides
US7560436B2 (en) 2005-02-22 2009-07-14 The Regents Of The University Of California Methods of treating gastrointestinal inflammation
US20060241076A1 (en) 2005-04-26 2006-10-26 Coley Pharmaceutical Gmbh Modified oligoribonucleotide analogs with enhanced immunostimulatory activity
AU2006301230A1 (en) 2005-10-12 2007-04-19 Cancer Research Technology Ltd. Methods and compositions for treating immune disorders
AU2006304205C1 (en) 2005-10-12 2012-11-15 Idera Pharmaceuticals, Inc. Immune regulatory oligonucleotide (IRO) compounds to modulate toll-like receptor based immune response
BRPI0618473A2 (pt) 2005-11-11 2011-08-30 Pfizer combinações e métodos de uso de um oligodeoxinucleotìdeo imunomodulador
DK1951870T3 (da) 2005-11-25 2013-07-29 Mologen Ag DNA-konstrukter til specifik inhibering af genekspression ved RNA-interferens
AU2006318464B2 (en) 2005-11-25 2011-02-17 Zoetis Belgium Sa Immunostimulatory oligoribonucleotides
CA2641026A1 (en) 2006-02-01 2007-08-09 The Johns Hopkins University Polypeptide-nucleic acid conjugate for immunoprophylaxis or immunotherapy for neoplastic or infectious disorders
WO2007131495A2 (de) * 2006-05-11 2007-11-22 Mologen Ag Multimer zur immunstimulation
WO2007147007A2 (en) 2006-06-13 2007-12-21 Bayhill Therapeutics, Inc. Methods and immune modulatory nucleic acid compositions for preventing and treating disease
EP2486938B1 (en) 2006-09-26 2018-05-09 Infectious Disease Research Institute Vaccine composition containing synthetic adjuvant
US20090181078A1 (en) 2006-09-26 2009-07-16 Infectious Disease Research Institute Vaccine composition containing synthetic adjuvant
US20080260820A1 (en) 2007-04-19 2008-10-23 Gilles Borrelly Oral dosage formulations of protease-resistant polypeptides
EP3246409A1 (en) 2007-05-29 2017-11-22 Nature Technology Corporation Antibiotic-resistance-free vectors
EA018456B1 (ru) 2007-07-27 2013-08-30 Имматикс Байотекнолоджиз Гмбх Новые иммуногенные эпитопы для иммунотерапии
WO2009035554A2 (en) 2007-09-07 2009-03-19 University Of Florida Research Foundation, Inc. Superior structure stability and selectivity of hairpin nucleic acid probes with an l-dna stem
KR20100068422A (ko) 2007-10-09 2010-06-23 콜리 파마슈티칼 게엠베하 변경된 당 잔기를 함유하는 면역자극성 올리고뉴클레오티드 유사체
EP2058397A1 (de) 2007-11-07 2009-05-13 Mologen AG Multimeres Assemblat zur Immunstimulation
WO2009069447A1 (ja) 2007-11-28 2009-06-04 Toray Industries, Inc. インフルエンザワクチン用のアジュバント及びインフルエンザワクチン
WO2009069682A1 (ja) 2007-11-28 2009-06-04 Toray Industries, Inc. 肝炎の治療剤又は予防剤
WO2010039137A1 (en) 2008-10-02 2010-04-08 Idera Pharmaceuticals, Inc. Immune regulatory oligonucleotide (iro) compounds to modulate toll-like receptor based immune response
EP2246433A1 (de) 2009-04-30 2010-11-03 Mologen AG Concatemere zur Immunmodulation
CN103221065A (zh) 2010-03-26 2013-07-24 葛兰素史密斯克莱生物公司 Hiv疫苗
GB201021867D0 (en) * 2010-12-23 2011-02-02 Mologen Ag Non-coding immunomodulatory DNA construct
GB201021873D0 (en) 2010-12-23 2011-02-02 Mologen Ag DNA expression construct
JP5761707B2 (ja) 2011-02-02 2015-08-12 国立研究開発法人産業技術総合研究所 高効率細胞融合法
SG10201704992SA (en) * 2012-06-21 2017-07-28 Compugen Ltd Lsr antibodies, and uses thereof for treatment of cancer
GB2514591A (en) 2013-05-30 2014-12-03 Mologen Ag Predictive biomarker for cancer therapy
GB2523187A (en) * 2014-02-18 2015-08-19 Mologen Ag Covalently closed non-coding immunomodulatory DNA construct
LU92821B1 (en) 2015-09-09 2017-03-20 Mologen Ag Combination comprising immunostimulatory oligonucleotides
GB2542425A (en) 2015-09-21 2017-03-22 Mologen Ag Means for the treatment of HIV
EP3392345A1 (en) 2017-04-22 2018-10-24 Mologen AG Biomarker for small cell lung cancer therapy
TW201919652A (zh) 2017-08-31 2019-06-01 德商摩洛基公司 調節腫瘤微環境之ｔｌｒ－９促效劑

Also Published As

Publication number Publication date
CN108138179A (zh) 2018-06-08
LU92821B1 (en) 2017-03-20
RU2766693C2 (ru) 2022-03-15
IL257921A (en) 2018-05-31
CN108138179B (zh) 2022-05-13
RU2018108353A3 (ru) 2020-02-28
US10487333B2 (en) 2019-11-26
PL3347468T3 (pl) 2022-03-21
EP3347468B1 (en) 2021-12-15
EP3347468A1 (en) 2018-07-18
US20190316134A1 (en) 2019-10-17
US10604760B2 (en) 2020-03-31
AU2016319214B2 (en) 2021-12-23
SI3347468T1 (sl) 2022-02-28
PT3347468T (pt) 2022-02-18
ZA201801001B (en) 2019-05-29
JP2022060368A (ja) 2022-04-14
KR20180050309A (ko) 2018-05-14
MX2018002665A (es) 2018-06-13
CA2997319A1 (en) 2017-03-16
US11578331B2 (en) 2023-02-14
JP2021059566A (ja) 2021-04-15
HK1257273A1 (en) 2019-10-18
US20180251767A1 (en) 2018-09-06
JP2018530530A (ja) 2018-10-18
IL257921B (en) 2022-09-01
ES2905891T3 (es) 2022-04-12
US20210010003A1 (en) 2021-01-14
CA2997319C (en) 2023-01-10
WO2017042336A1 (en) 2017-03-16
BR112018004246A2 (pt) 2018-09-25
KR102411799B1 (ko) 2022-06-23
AU2016319214A1 (en) 2018-03-15
JP7436535B2 (ja) 2024-02-21

Similar Documents

Publication Publication Date Title
RU2018108353A (ru) Комбинация, включающая иммуностимулирующие олигонуклеотиды
JP2018530530A5 (ru)
Kalarikkal et al. Edible plant-derived exosomal microRNAs: Exploiting a cross-kingdom regulatory mechanism for targeting SARS-CoV-2
Ni et al. Chemical modifications of nucleic acid aptamers for therapeutic purposes
CA3107683A1 (en) Compositions comprising circular polyribonucleotides and uses thereof
HRP20211619T1 (hr) Poboljšana formulacija lipida
Xiong et al. Targeting G-quadruplex nucleic acids with heterocyclic alkaloids and their derivatives
JP2010166916A5 (ru)
ES2553877T3 (es) 5'-trifosfato-oligonucleótido con extremo romo y sus utilizaciones
Bishani et al. Activation of innate immunity by therapeutic nucleic acids
US20170268001A1 (en) Rnas with tumor radio/chemo-sensitizing and immunomodulatory properties and methods of their preparation and application
RU2015119409A (ru) Конъюгаты олигонуклеотидов
JP2014533953A (ja) 治療用ｒｎａスイッチ組成物及び使用方法
US20240141346A1 (en) Targeted inhibition using engineered oligonucleotides
RU2015120645A (ru) Композиции и способы модуляции экспрессии рецептора фактора роста фибробластов 3 типа (fgfr3)
JP2019506862A5 (ru)
JP2012505657A5 (ru)
RU2014125496A (ru) Комбинированная терапия для лечения нарушений слуха и равновесия
WO2013064584A1 (en) Double-stranded RNA for immunostimulation
JP2011524745A5 (ru)
JP2013537404A5 (ru)
EA201691786A1 (ru) Композиции олигонуклеотидов и способы их получения
CN105899663A (zh) 用于基因表达控制的人工模拟miRNA及其用途
PE20240640A1 (es) Administracion oral de oligonucleotidos
JP2017529834A5 (ru)

Legal Events

Date Code Title Description
FA92 Acknowledgement of application withdrawn (lack of supplementary materials submitted)

Effective date: 20200805

FZ9A Application not withdrawn (correction of the notice of withdrawal)

Effective date: 20210624

HE9A Changing address for correspondence with an applicant
HZ9A Changing address for correspondence with an applicant